Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02971891 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
A Phase 3 study, sponsored by Maruho Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 484
- Enrollment target
NCT02971891 is a Phase 3 study that has completed, run by Maruho Co.. The registered enrollment target is 484 participants.
The verdict
NCT02971891, a Phase 3 study, has completed, sponsored by Maruho Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 484 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).
Interventions
- DRUG Vehicle Topical Gel
- DRUG CLS006 (Furosemide) Topical Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2017-01 |
| Est. Completion | 2018-07-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02971891
The ClinicalTrials.gov registry entry for NCT02971891 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maruho Co., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Topical Gel is the first listed.
NCT02971891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02971891 about?
NCT02971891 is a clinical study titled "A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts". To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).
What is the current status of trial NCT02971891?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 484 participants. The study started on 2017-01. Estimated completion is 2018-07-10.
What interventions are being tested in trial NCT02971891?
The interventions under investigation include: Vehicle Topical Gel (DRUG), CLS006 (Furosemide) Topical Gel (DRUG).
Who is sponsoring clinical trial NCT02971891?
This trial is sponsored by Maruho Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.